ReviewCancer medicine2024
Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.
Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Preoperative gamma-glutamyltransferase-to-lymphocyte ratio and prognosis after curative hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Meta-analysis of multimodal analgesia for reducing postoperative wound pain after hepatectomy for hepatocellular carcinoma.Scientific reports · 2025Pooled it
- Mapping the knowledge domains of literature on hepatocellular carcinoma and liver failure: a bibliometric approach.Frontiers in oncology · 2025Pooled it
- Preoperative C-reactive protein to albumin ratio may be a good prognostic marker in patients undergoing hepatectomy for hepatocellular carcinoma: a meta-analysis.Frontiers in nutrition · 2024Pooled it
- Development and internal-external validation of a risk prediction model for acute pain after HAIC for patients with liver cancer using logistic regression and XGBoost algorithm.Asia-Pacific journal of oncology nursing · 2026Article
- Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.Surgery today · 2026Article
- A recurrence risk prediction model and recurrence patterns in pulmonary lymphoepithelial carcinoma based on clinical and dynamic hematologic parameters.Translational lung cancer research · 2026Article
- Article
- An inflammation-nutrition-surgery-based INSEP model and a web-based clinical decision support system for predicting early postoperative infection in elderly patients with hepatocellular carcinoma: a multicenter retrospective study.Frontiers in nutrition · 2026Article
- Riboflavin (VB2) inhibits hepatocellular carcinogenesis by enhancing retinol metabolism and suppressing cell proliferation in Hras12V transgenic mice.Frontiers in oncology · 2026Article
- Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Review
- Significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio as prognostic predictors after liver transplantation.World journal of transplantation · 2025Article
- Immune and Inflammation Markers as a Predictor of Overall Survival in Patients with Hematologic Malignancies: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- A Predictive Model for Acute Kidney Injury Based on Leukocyte-Related Indicators in Hepatocellular Carcinoma Patients Admitted to the Intensive Care Unit.Mediators of inflammation · 2025Article
- Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.World journal of gastroenterology · 2024Article
- Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.Cancer medicine · 2024Review
- Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Deep learning radiomics based on contrast enhanced MRI for preoperatively predicting early recurrence in hepatocellular carcinoma after curative resection.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Hepatectomy remains the first-line treatment for patients with resectable HCC. However, the reported recurrence rate of HCC at 5 years after surgery is between 50% and 70%. Tumor-related factors, including tumor size, number and differentiation, and underlying liver disease are well-known risk factors for recurrence after treatment. In addition to tumor-related factors, ever-increasing amounts of studies are finding that the tumor microenvironment also plays an important role in the recurrence of HCC, including systemic inflammatory response and immune regulation. Based on this, some inflammatory and immune markers were used in predicting postoperative cancer recurrence. These include neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, cytotoxic T cells, and regulatory T cells, among others. In this review, we summarized the inflammatory and immune markers that affect recurrence after HCC resection in order to provide direction for adjuvant therapy after HCC resection and ultimately achieve the goal of reducing recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.